Xilio Therapeutics, Inc. (XLO) Dividend History

Company News

• Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

  Xilio Therapeutics announced the closing of a $50.0 million public offering, with the potential for up to $150.0 million in total gross proceeds if all warrants are exercised. The financing was co-led by new investors Coastlands Capital and Frazier Life Sciences, and included participation from Gilead Sciences, Logos Capital, and Samsara BioCapital.

  GlobeNewswire Inc.

  Featured Companies: GILD
• Xilio Therapeutics Announces Proposed Public Offering

  Xilio Therapeutics, a clinical-stage biotechnology company, announced a proposed public offering of pre-funded warrants, Series A, B, and C warrants to purchase shares of common stock. The company plans to use the net proceeds to advance the development of its product candidates and for general corporate purposes.

  Benzinga
• Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

  Xilio Therapeutics announced updated Phase 2 data for its tumor-activated anti-CTLA-4 drug vilastobart in combination with atezolizumab, showing a 26% preliminary objective response rate in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer without liver metastases.

  GlobeNewswire Inc.
• Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

  Xilio Therapeutics reported progress in its pipeline, including positive initial Phase 2 data for its tumor-activated anti-CTLA-4 therapy vilastobart in metastatic microsatellite stable colorectal cancer. The company also announced a collaboration with AbbVie to develop novel tumor-activated immunotherapies.

  GlobeNewswire Inc.

  Featured Companies: ABBV
• RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034

  The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.

  GlobeNewswire Inc.

  Featured Companies: ALNY BNTC IONS